drugset / Trial / NCT06270433

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

NCT06270433

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of anhedonia in patients with major depression disorder compared to desvenlafaxine succinate sustained-release tablets, to provide evidence-based basis for clinical rational drug use.

Timeline

Start
2024-02-19
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desvenlafaxine Other / unclassified 50 mg Oral
Subject Toludesvenlafaxine Small molecule 80 mg Oral
Subject Toludesvenlafaxine Small molecule 120 mg Oral
Subject Toludesvenlafaxine Small molecule 160 mg Oral